Business
Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting
PALO ALTO, Calif., April 25, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel
About this update from Kodiak Sciences Inc
[{"type":"text","content":"PALO ALTO, Calif., April 25, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, being held from April 28 – May 2 in Vancouver, Canada.\n\n \n\"The clinical and preclinical data being presented at ARVO's Annual Meeting provide early evidence of the safety and efficacy of Kodiak's novel antibody biopolymer conjugates. It's exciting to see the preclinical science and thoughtful design underlying our ABC Platform begin to translate into clinical utility with our Phase 1 study of KSI-301, an anti-VEGF ABC being developed as a new and potentially better therapy for the most prevalent retinal vascular diseases like wet AMD, diabetic eye disease and retinal vein occlusion. At ARVO, we will also be presenting preclinical data on KSI-501, demonstrating how the ABC Platform can simultaneously target multiple biologies of relevance in multifactorial diseases,\" said Jason Ehrlich, M.D., Ph.D., Kodiak's Chief Medical Officer and Chief Development Officer. \"We also look forward to presenting data from our ongoing Phase 1b multiple-dose study of KSI-301 at upcoming medical meetings later this year.\"\nDetails of the presentations are as follows:\nTitle: Chronic Nonclinical Ocular Toxicity Study of KSI-301 Demonstrates Tolerability after Intravitreal Administration in Cynomolgus MonkeysPresenter: John Sinclair, Director, Nonclinical Development and Safety Evaluation, Kodiak SciencesPresentation date and time: April 28; 8:00 – 9:45 AM PT\nTitle: Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durabilityPresenter: Sunil Patel, M.D., Ph.D., Retina Research Institute of TexasPresentation date and time: April 30; 11:45 AM – 1:30 PM PT\nTitle: Development of Novel Bispecific Anti-Inflammatory and Anti-Angiogenic Therapy for the Treatment of both Retinal Vascular and Inflammatory DiseasesPresenter: Fernando Corrêa, Ph.D., Associate Principal Scientist, Kodiak SciencesPresentation date and time: May 1; 3:00 – 4:45 PM PT\nAbout KSI-301\nKSI-301 is an investigational therapy built on the Company's ABC Platform and is...